A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Science Translational Medicine

Volumn 9, Issue 399, 2017, Pages

  O'Rourke, Donald M ^a   Nasrallah, Maclean P ^a   Desai, Arati ^a   Melenhorst, Jan J ^a   Mansfield, Keith ^b   Morrissette, Jennifer J D ^a   Martinez Lage, Maria ^a,e   Brem, Steven ^a   Maloney, Eileen ^a   Shen, Angela ^c   Isaacs, Randi ^b   Mohan, Suyash ^a   Plesa, Gabriela ^a   Lacey, Simon F ^a   Navenot, Jean Marc ^a   Zheng, Zhaohui ^a   Levine, Bruce L ^a   Okada, Hideho ^d   June, Carl H ^a   Brogdon, Jennifer L ^b   Maus, Marcela V ^e   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL EXPANSION; CELL MIGRATION; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPOTENSION; LUNG DISEASE; LYMPHOCYTIC INFILTRATION; MALE; NEUROLOGIC DISEASE; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RASH; SEIZURE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; BIOLOGICAL THERAPY; BRAIN TUMOR; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; TUMOR RECURRENCE;

AGED; BRAIN NEOPLASMS; CELL- AND TISSUE-BASED THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL;

EID: 85025480254     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa0984     Document Type: Article

References (51)

1. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. B. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, R. O. Mirimanoff; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. A. S. Chi, A. D. Norden, P. Y. Wen, Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6, 513-526 (2009).
3. J. J. C. Verhoeff, O. van Tellingen, A. Claes, L. J. A. Stalpers, M. E. van Linde, D. J. Richel, W. P. J. Leenders, W. R. van Furth, Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444 (2009).
4. S. Sathornsumetee, D. A. Reardon, Targeting multiple kinases in glioblastoma multiforme. Expert Opin. Investig. Drugs 18, 277-292 (2009).
5. R. Stupp, S. Taillibert, A. A. Kanner, S. Kesari, D. M. Steinberg, S. A. Toms, L. P. Taylor, F. Lieberman, A. Silvani, K. L. Fink, G. H. Barnett, J.-J. Zhu, J. W. Henson, H. H. Engelhard, T. C. Chen, D. D. Tran, J. Sroubek, N. D. Tran, A. F. Hottinger, J. Landolfi, R. Desai, M. Caroli, Y. Kew, J. Honnorat, A. Idbaih, E. D. Kirson, U. Weinberg, Y. Palti, M. E. Hegi, Z. Ram, Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA 314, 2535-2543 (2015).
6. C. G. Patil, A. Yi, A. Elramsisy, J. Hu, D. Mukherjee, D. K. Irvin, J. S. Yu, S. I. Bannykh, K. L. Black, M. Nuño, Prognosis of patients with multifocal glioblastoma: A case-control study. J. Neurosurg. 117, 705-711 (2012).
7. A. L. Rivera, C. E. Pelloski, M. R. Gilbert, H. Colman, C. De La Cruz, E. P. Sulman, B. N. Bekele, K. D. Aldape, MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 12, 116-121 (2010).
8. M. Esteller, J. Garcia-Foncillas, E. Andion, S. N. Goodman, O. F. Hidalgo, V. Vanaclocha, S. B. Baylin, J. G. Herman, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
9. G. Li, A. J. Wong, EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev. Vaccines 7, 977-985 (2008).
10. E. Padfield, H. P. Ellis, K. M. Kurian, Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front. Oncol. 5, 5 (2015).
11. A. B. Heimberger, D. Suki, D. Yang, W. Shi, K. Aldape, The natural history of EGFR and EGFRvIII in glioblastoma patients. J. Transl. Med. 3, 38 (2005).
12. A. B. Heimberger, R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R. Sawaya, K. Aldape, Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 11, 1462-1466 (2005).
13. E. S. Tykocinski, R. A. Grant, G. S. Kapoor, J. Krejza, L.-E. Bohman, T. A. Gocke, S. Chawla, C. H. Halpern, J. Lopinto, E. R. Melhem, D. M. O'Rourke, Use of magnetic perfusionweighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol. 14, 613-623 (2012).
14. A. H. Thorne, C. Zanca, F. Furnari, Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. 18, 914-918 (2016).
15. J. Schuster, R. K. Lai, L. D. Recht, D. A. Reardon, N. A. Paleologos, M. D. Groves, M. M. Mrugala, R. Jensen, J. M. Baehring, A. Sloan, G. E. Archer, D. D. Bigner, S. Cruickshank, J. A. Green, T. Keler, T. A. Davis, A. B. Heimberger, J. H. Sampson, A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. Neuro Oncol. 17, 854-861 (2015).
16. J. H. Sampson, A. B. Heimberger, G. E. Archer, K. D. Aldape, A. H. Friedman, H. S. Friedman, M. R. Gilbert, J. E. Herndon II, R. E. McLendon, D. A. Mitchell, D. A. Reardon, R. Sawaya, R. J. Schmittling, W. Shi, J. J. Vredenburgh, D. D. Bigner, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722-4729 (2010).
17. S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
18. C. J. Turtle, L.-A. Hanafi, C. Berger, T. A. Gooley, S. Cherian, M. Hudecek, D. Sommermeyer, K. Melville, B. Pender, T. M. Budiarto, E. Robinson, N. N. Steevens, C. Chaney, L. Soma, X. Chen, C. Yeung, B. Wood, D. Li, J. Cao, S. Heimfeld, M. C. Jensen, S. R. Riddell, D. G. Maloney, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123-2138 (2016).
19. D. L. Porter, W.-T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, A. Bagg, K. T. Marcucci, A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. Melenhorst, C. H. June, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
20. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim, R. P. T. Somerville, R. O. Carpenter, M. Stetler-Stevenson, J. C. Yang, G. Q. Phan, M. S. Hughes, R. M. Sherry, M. Raffeld, S. Feldman, L. Lu, Y. F. Li, L. T. Ngo, A. Goy, T. Feldman, D. E. Spaner, M. L. Wang, C. C. Chen, S. M. Kranick, A. Nath, D.-A. Nathan, K. E. Morton, M. A. Toomey, S. A. Rosenberg, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
21. M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg, P. Hwu, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 (Pt. 1), 6106-6115 (2006).
22. G. L. Beatty, A. R. Haas, M. V. Maus, D. A. Torigian, M. C. Soulen, G. Plesa, A. Chew, Y. Zhao, B. L. Levine, S. M. Albelda, M. Kalos, C. H. June, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112-120 (2014).
23. N. Ahmed, V. S. Brawley, M. Hegde, C. Robertson, A. Ghazi, C. Gerken, E. Liu, O. Dakhova, A. Ashoori, A. Corder, T. Gray, M.-F. Wu, H. Liu, J. Hicks, N. Rainusso, G. Dotti, Z. Mei, B. Grilley, A. Gee, C. M. Rooney, M. K. Brenner, H. E. Heslop, W. S. Wels, L. L. Wang, P. Anderson, S. Gottschalk, Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688-1696 (2015).
24. C. E. Brown, D. Alizadeh, R. Starr, L. Weng, J. R. Wagner, A. Naranjo, J. R. Ostberg, M. S. Blanchard, J. Kilpatrick, J. Simpson, A. Kurien, S. J. Priceman, X. Wang, T. L. Harshbarger, M. D'Apuzzo, J. A. Ressler, M. C. Jensen, M. E. Barish, M. Chen, J. Portnow, S. J. Forman, B. Badie, Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561-2569 (2016).
25. M. Ohno, T. Ohkuri, A. Kosaka, K. Tanahashi, C. H. June, A. Natsume, H. Okada, Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J. Immunother. Cancer 1, 21 (2013).
26. L. A. Johnson, J. Scholler, T. Ohkuri, A. Kosaka, P. R. Patel, S. E. McGettigan, A. K. Nace, T. Dentchev, P. Thekkat, A. Loew, A. C. Boesteanu, A. P. Cogdill, T. Chen, J. A. Fraietta, C. C. Kloss, A. D. Posey Jr., B. Engels, R. Singh, T. Ezell, N. Idamakanti, M. H. Ramones, N. Li, L. Zhou, G. Plesa, J. T. Seykora, H. Okada, C. H. June, J. L. Brogdon, M. V. Maus, Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22 (2015).
27. M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, M. R. Gilbert, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26, 4189-4199 (2008).
28. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
29. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
30. B. L. Levine, J. Miskin, K. Wonnacott, C. Keir, Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92-101 (2017).
31. S. L. Maude, D. Barrett, D. T. Teachey, S. A. Grupp, Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119-122 (2014).
32. D. T. Teachey, S. R. Rheingold, S. L. Maude, G. Zugmaier, D. M. Barrett, A. E. Seif, K. E. Nichols, E. K. Suppa, M. Kalos, R. A. Berg, J. C. Fitzgerald, R. Aplenc, L. Gore, S. A. Grupp, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 121, 5154-5157 (2013).
33. D. T. Teachey, S. F. Lacey, P. A. Shaw, J. J. Melenhorst, S. L. Maude, N. Frey, E. Pequignot, V. E. Gonzalez, F. Chen, J. Finklestein, D. M. Barrett, S. L. Weiss, J. C. Fitzgerald, R. A. Berg, R. Aplenc, C. Callahan, S. R. Rheingold, Z. Zheng, S. Rose-John, J. C. White, F. Nazimuddin, G. Wertheim, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
34. C. M. Paulos, M. M. Suhoski, G. Plesa, T. Jiang, S. Basu, T. N. Golovina, S. Jiang, N. A. Aqui, D. J. Powell Jr., B. L. Levine, R. G. Carroll, J. L. Riley, C. H. June, Adoptive immunotherapy: Good habits instilled at youth have long-term benefits. Immunol. Res. 42, 182-196 (2008).
35. W. Wang, X. Wang, R. Doddareddy, D. Fink, T. McIntosh, H. M. Davis, H. Zhou, Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD)modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J. 16, 129-139 (2014).
36. F. Chen, D. T. Teachey, E. Pequignot, N. Frey, D. Porter, S. L. Maude, S. A. Grupp, C. H. June, J. J. Melenhorst, S. F. Lacey, Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods 434, 1-8 (2016).
37. S. A. Grossman, X. Ye, G. Lesser, A. Sloan, H. Carraway, S. Desideri, S. Piantadosi, NABTT CNS Consortium, Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin. Cancer Res. 17, 5473-5480 (2011).
38. H. Okada, M. Weller, R. Huang, G. Finocchiaro, M. R. Gilbert, W. Wick, B. M. Ellingson, N. Hashimoto, I. F. Pollack, A. A. Brandes, E. Franceschi, C. Herold-Mende, L. Nayak, A. Panigrahy, W. B. Pope, R. Prins, J. H. Sampson, P. Y. Wen, D. A. Reardon, Immunotherapy response assessment in neuro-oncology: A report of the RANO working group. Lancet Oncol. 16, e534-e542 (2015).
39. D. A. Reardon, H. Okada, Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J. Neurooncol 123, 339-346 (2015).
40. D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall, Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
41. G. G. Laport, B. L. Levine, E. A. Stadtmauer, S. J. Schuster, S. M. Luger, S. Grupp, N. Bunin, F. J. Strobl, J. Cotte, Z. Zheng, B. Gregson, P. Rivers, R. H. Vonderheide, D. N. Liebowitz, D. L. Porter, C. H. June, Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102, 2004-2013 (2003).
42. A. H. Long, W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J.Walker, M. E. Kohler, V. R. Venkateshwara, R. N. Kaplan, G. H. Patterson, T. J. Fry, R. J. Orentas, C. L. Mackall, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581-590 (2015).
43. O. U. Kawalekar, R. S. O'Connor, J. A. Fraietta, L. Guo, S. E. McGettigan, A. D. Posey Jr., P. R. Patel, S. Guedan, J. Scholler, B. Keith, N. W. Snyder, I. A. Blair, M. C. Milone, C. H. June, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380-390 (2016).
44. A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, T. Milliron, S. Westphal, J. Cotte, H. Huynh, A. Cannon, S. Yanovich, G. Akpek, M. Tan, K. Virts, K. Ruehle, C. Harris, S. Philip, R. H. Vonderheide, B. L. Levine, C. H. June, Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15, 4499-4507 (2009).
45. K. Sasaki, X. Zhu, C. Vasquez, F. Nishimura, J. E. Dusak, J. Huang, M. Fujita, A. Wesa, D. M. Potter, P. R. Walker, W. J. Storkus, H. Okada, Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 67, 6451-6458 (2007).
46. M. J. van den Bent, Y. Gao, M. Kerkhof, J. M. Kros, T. Gorlia, K. van Zwieten, J. Prince, S. van Duinen, P. A. Sillevis Smitt, M. Taphoorn, P. J. French, Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 17, 935-941 (2015).
47. C. A. Del Vecchio, K. C. Jensen, R. T. Nitta, A. H. Shain, C. P. Giacomini, A. J. Wong, Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res. 72, 2657-2671 (2012).
48. C. A. Del Vecchio, C. P. Giacomini, H. Vogel, K. C. Jensen, T. Florio, A. Merlo, J. R. Pollack, A. J. Wong, EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 32, 2670-2681 (2013).
49. L. Palma, N. Di Lorenzo, B. Guidetti, Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J. Neurosurg. 49, 854-861 (1978).
50. W. H. Brooks, W. R. Markesbery, G. D. Gupta, T. L. Roszman, Relationship of lymphocyte invasion and survival of brain tumor patients. Ann. Neurol. 4, 219-224 (1978).
51. S. Janetzki, C. M. Britten, M. Kalos, H. I. Levitsky, H. T. Maecker, C. J. M. Melief, L. J. Old, P. Romero, A. Hoos, M. M. Davis, "MIATA"-Minimal information about T cell assays. Immunity 31, 527-528 (2009).